Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls.
Helena AebersoldFabienne Foster-WitassekMiquel Serra-BurrielBeat BrünggerStefanie AeschbacherJürg-Hans BeerEva BlozikManuel BlumLeo BonatiDavid ConenGiulio ConteStefan FelderCarola A HuberMichael KuehneGiorgio MoschovitisAndreas MuellerRebecca E PaladiniTobias ReichlinNicolas RodondiAnne SpringerAnnina StauberChristian SticherlingThomas SzucsStefan OsswaldMatthias Schwenkglenksnull nullPublished in: BMJ open (2023)
We robustly found direct medical costs of AF patients were 50% higher than those of population-based controls. Such information on the incremental cost burden of AF may support healthcare capacity planning.
Keyphrases
- atrial fibrillation
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- heart failure
- oral anticoagulants
- left atrial
- left atrial appendage
- catheter ablation
- peritoneal dialysis
- direct oral anticoagulants
- health information
- percutaneous coronary intervention
- coronary artery disease
- left ventricular
- patient reported outcomes
- patient reported